Resource impact summary report
Resource impact summary report
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect local data and assumptions.
Recommendation
NICE has recommended molnupiravir as an option for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test, only if:
-
they have 1 or more risk factors for progression to severe COVID-19 (as defined in section 5 of NICE's technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19) and
-
both nirmatrelvir plus ritonavir and sotrovimab are contraindicated or unsuitable.
Treatment options for the eligible population
The comparator treatments for the eligible population are nirmatrelvir plus ritonavir, and sotrovimab.
Molnupiravir, and nirmatrelvir plus ritonavir, are both administered orally. Sotrovimab is administered as 1 intravenous infusion.
For more information about the treatments, such as dose and average treatment duration, see the resource impact template.
Financial resource impact (cash items)
The list price for molnupiravir is confidential until molnupiravir is commercially available.
Users can input the confidential price of molnupiravir and amend other variables in the resource impact template.
The payment mechanism for the technology is determined by the responsible commissioner and depends on the technology being classified as high cost.
-
We expect the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £8,800 per 100,000 population, based on a population for England of 57.16 million people).
-
This is because the technology is a further treatment option and the overall cost of treatment will be similar for this population, and we do not think practice will change substantially as a result of this guidance.
For further analysis or to calculate the financial impact of cash items, see the resource impact template.
Capacity impact
To calculate the financial capacity impact from a commissioner (national) and provider (local) perspective, see the resource impact template.
Key information
| Time from publication to routine commissioning funding |
90 days |
|---|---|
| Programme budgeting category |
PBC 01x infectious diseases |
| Commissioner(s) |
Integrated care boards |
| Provider(s) |
Primary care providers and NHS hospital trusts |
| Pathway position |
Provided when both nirmatrelvir plus ritonavir, and sotrovimab, are contraindicated or unsuitable |
About this resource impact summary report
This resource impact summary report accompanies the NICE technology appraisal guidance on molnupiravir for treating COVID-19 and should be read with it. See terms and conditions on the NICE website.
ISBN: 978-1-4731-6968-5
This page was last updated: